Washington, D.C. – The Medical Imaging & Technology Alliance (MITA) – the leading trade association representing manufacturers of medical imaging equipment, radiopharmaceuticals, contrast media, and focused ultrasound therapeutic devices – has submitted comments in response to the Centers for Medicare & Medicaid Services (CMS) Proposed Decision Memorandum for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease.

"MITA strongly believes the current proposal to limit coverage to randomized controlled trials in the hospital outpatient setting will significantly limit beneficiaries from accessing both current and potential innovations in Alzheimer's treatment," said Patrick Hope, executive director of MITA. "We encourage CMS to revisit this coverage determination with special consideration of its impact on innovation in the diagnosis, treatment and care for those Americans living with Alzheimer's disease."

In its comments, MITA also stressed its belief that Medicare's final decision should allow both coverage of amyloid PET and also ensure that the right patients will have access to amyloid reduction therapies.

About MITA
MITA is the collective voice of manufacturers of medical imaging equipment, radiopharmaceuticals, contrast media, and focused ultrasound therapeutic devices. It represents companies whose sales comprise more than 90 percent of the global market for medical imaging innovations. These products include: magnetic resonance imaging (MRI), medical X-Ray equipment, computed tomography (CT) scanners, ultrasound, nuclear imaging, radiopharmaceuticals, and imaging information systems. MITA Member company technologies are an important part of our nation's healthcare infrastructure and are essential for the screening, diagnosis, staging, managing, and effectively treating patients with cancer, heart disease, neurological degeneration, and numerous other medical conditions.

Molecular Imaging Homepage